We are live on ! Find out more
CYCN icon

Cyclerion Therapeutics
CYCN

17 hedge funds and large institutions have $2.41M invested in Cyclerion Therapeutics in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

13% more funds holding

Funds holding: 15 → 17 (+2)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.68% less ownership

Funds ownership: 39.49% → 38.81% (-0.68%)

30% less capital invested

Capital invested by funds: $3.42M → $2.41M (-$1.01M)

Holders
17
Holders Change
+2
Holders Change %
+13.33%
% of All Funds
0.25%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
3
Increased
4
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$5.39K
2
TRCT
Tower Research Capital (TRC)
New York
+$4.07K
3
UBS Group
UBS Group
Switzerland
+$517
4
AWM
Activest Wealth Management
Florida
+$284
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$182

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$60.6K
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.58K
3
Wells Fargo
Wells Fargo
California
-$48
Name Holding Trade Value Shares
Change 		Change in
Stake
SPC
1
Slate Path Capital
New York
$823K – – –
MP
2
MFN Partners
Massachusetts
$386K – – –
TCP
3
Tyndall Capital Partners
New York
$379K – – –
Fidelity Investments
4
Fidelity Investments
Massachusetts
$368K -$2.58K -908 -0.6%
AG
5
Artal Group
Luxembourg
$271K -$60.6K -21,312 -15%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$77.5K +$5.39K +1,896 +6%
Vanguard Group
7
Vanguard Group
Pennsylvania
$54K – – –
BlackRock
8
BlackRock
New York
$39.5K – – –
UBS Group
9
UBS Group
Switzerland
$6.22K +$517 +182 +7%
TRCT
10
Tower Research Capital (TRC)
New York
$3.37K +$4.07K +1,431 +4,336%
Morgan Stanley
11
Morgan Stanley
New York
$1.49K – – –
Group One Trading
12
Group One Trading
Illinois
$1.23K – – –
Royal Bank of Canada
13
Royal Bank of Canada
Ontario, Canada
$1K +$182 +64 +18%
AWM
14
Activest Wealth Management
Florida
$230 +$284 +100 New
Bank of America
15
Bank of America
North Carolina
$37 +$45 +16 New
PNC Financial Services Group
16
PNC Financial Services Group
Pennsylvania
$5 +$6 +2 New
Northwestern Mutual Wealth Management
17
Northwestern Mutual Wealth Management
Wisconsin
$2 – – –
Wells Fargo
18
Wells Fargo
California
– -$48 -15 Closed

CYCN Hedge Fund Activity: Q2 2024 in Review

17 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q2 2024, worth a combined $2.41M — down 30% from $3.42M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new CYCN positions and 1 closed out — a net gain of 2 holders — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $5.39K. The largest seller was Artal Group, cutting an estimated $60.6K.

  • 17 institutional investors held Cyclerion Therapeutics (CYCN) as of Q2 2024, up from 15 in Q1 2024.
  • Funds reported $2.41M of Cyclerion Therapeutics stock for Q2 2024, down 30% quarter-over-quarter.
  • 3 funds opened new Cyclerion Therapeutics positions in Q2 2024 and 1 closed out, a net change of +2 holders.
  • The largest Cyclerion Therapeutics buyer in Q2 2024 was Geode Capital Management, an estimated $5.39K added.
  • The largest Cyclerion Therapeutics seller in Q2 2024 was Artal Group, an estimated $60.6K sold.

Based on aggregated 13F filings for Q2 2024.